KPMG-INTERNATIONAL
14.10.2020 06:03:13 CEST | Business Wire | Press release
As General Counsel and in-house legal teams contend with the increasing pressures facing their organizations in the wake of COVID-19, there is an urgent need to rethink delivery models and transform legal function operations. While the move to digitize and automate the legal function was already underway before COVID-19, it is now a commercial imperative, and the scope and remit is wider than before as the pandemic situation has intensified the need for organizations to transform.
In response, a Global Legal Operations Transformation Services offering has been launched across KPMG firms, which is designed to provide clients with a wide range of global strategies and cross-border capabilities to help meet the challenges they face.
“I believe KPMG’s Global Legal Operations Transformation Services teams are ‘global,’ both in terms of the geographic coverage but also the strategies offered,” says Stuart Fuller , Head of Global Legal Services, KPMG International. “Practice leaders are senior, experienced, and work together in KPMG firms across Europe, the Americas and the Asia Pacific region. They have a laser focus on results, and they are delivering significant and measurable improvement for legal functions across KPIs, such as productivity, customer satisfaction and quality measures―results that are crucial for organizations in the current climate.”
The KPMG Legal Operations Transformation Services practice leadership team includes Andreas Bong , Nicola Brooks , Philipp Glock , Eric Gorman , Kimberly Tan Majure and David Murray , and with an imminent announcement of a significant further partner hire. These leaders are supported by their team members in country firms, and professionals across the global organization, including MBAs, lawyers, legal technologists, data scientists and specialists in operational excellence. Their diverse and complementary skillsets, and combined experience, unite under KPMG’s global methodology to provide significant value to clients.
“We draw on all of the strengths of KPMG professionals across our firms, not just in legal and technology, but also Lean Six Sigma, Human-Centred Design and Systems Thinking. Together, our organization has achieved a substantial track record of implementing and running the transformation opportunities that we identify,” says Fuller. “KPMG Law is a combination of skills and approaches: we have over 2,700 lawyers in 81 jurisdictions advising on complex advisory and regulatory matters, and large transactions; we also provide global solutions such as business reorganization, global entity management and mass claims, offering an integrated service and advice. The new Legal Operations Transformation Service enables KPMG firms to handle large-scale business in a more efficient and technologically-enabled way and is only the first in a number of capabilities and services that we plan to provide in this space.”
The Legal Operations Transformation Services team brings more than 14 years of credentials and experience in the legal transformation space, with recent and current engagements across multinational organizations in the financial services, asset management, automotive, insurance and consumer goods sectors. In the past two years alone, KPMG firms have delivered cost savings of more than US$200 million across a range of services, including process optimization, automation, contract life cycle management, managed services and productized legal solutions.
David Linke , the Global Head of Tax & Legal Services for KPMG International, says “KPMG firms have a record of innovation and success in Tax Transformation under the banner of ’Tax Reimagined.’ Legal Operations Transformation Services are one of KPMG firms’ leading service offerings. While COVID-19 has accelerated the trends that we were already seeing for legal transformation, the post-COVID world will require legal and compliance teams to be even more efficient, even more engaged with the business and to play a key role in driving the customer experience, revenue and cash conversion cycles. Never has a global and integrated approach to transformation been more in demand than in the current climate. KPMG professionals are focused on bringing the best of our global capabilities, expertise and solutions to legal departments.”
* Important note: Certain member firms of the KPMG global organization, including the US firm, KPMG LLP, do not provide legal services or have KPMG Law service entities. In the US, these Legal Operations Transformation Services will be provided through the Advisory and Tax functions. Some or all the services described herein may not be permissible for KPMG audit clients and their affiliates or related entities.
About KPMG International
KPMG is a global organization of independent professional services firms providing Audit, Tax and Advisory services. We operate in 147 countries and territories and have more than 219,000 people working in member firms around the world. Each KPMG firm is a legally distinct and separate entity and describes itself as such.
KPMG International Limited is a private English company limited by guarantee. KPMG International Limited and its related entities do not provide services to clients.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201013006153/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
